Interleukin-32 expression and Treg infiltration in esophageal squamous cell carcinoma

Anticancer Research

Volumn 35, Issue 5, 2015, Pages 2941-2948

  Nabeki, Bunpei ^a   Ishigami, Sumiya ^a,b   Uchikado, Yasuto ^a   Sasaki, Ken ^a   Kita, Yoshiaki ^a   Okumura, Hiroshi ^a   Arigami, Takaaki ^a   Kijima, Yuko ^a   Kurahara, Hiroshi ^a   Maemura, Kosei ^a   Natsugoe, Shoji ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Esophageal carcinoma; IL32; Immunsuppressive; Regulatory T cell; Survival

Indexed keywords

INTERLEUKIN 32; TRANSCRIPTION FACTOR FOXP3; IL32 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CELL INFILTRATION; CELL MEMBRANE; CONTROLLED STUDY; CYTOPLASM; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS RESECTION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PATHOLOGY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPLEEN CELL; STROMA; TUMOR INVASION; BIOSYNTHESIS; ESOPHAGUS TUMOR; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MIDDLE AGED; PROGNOSIS; SQUAMOUS CELL CARCINOMA;

AGED; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKINS; MALE; MIDDLE AGED; PROGNOSIS; T-LYMPHOCYTES, REGULATORY; TUMOR MARKERS, BIOLOGICAL;

EID: 84929667522     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Nishimaki T, Shimoji H and Sunagawa H: Recent changes and the future roles of esophageal cancer surgery. Ann Thorac Cardiovasc Surg 10: 324-332, 2004.
2. Ando N, Iizuka T, Ide H, Ishida K, Shinoda M, Nishimaki T, Takiyama W, Watanabe H, Isono K, Aoyama N, Makuuchi H, Tanaka O, Yamana H, Ikeuchi S, Kabuto T, Nagai K, Shimada Y, Kinjo Y and Fukuda H: Japan Clinical Oncology Group. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study - JCOG9204. J Clin Oncol 21: 4592-4596, 2003.
3. Natsugoe S, Matsumoto M, Okumura H, Ikeda M, Ishigami S, Owaki T, Takao S and Aikou T: Prognostic factors in patients with submucosal esophageal cancer. J Gastrointest Surg 8: 631-635, 2008.
4. Yasui W, Oue N, Kuniyasu H, Ito R, Tahara E and Yokozaki H: Molecular diagnosis of gastric cancer: present and future. Gastric Cancer 4: 113-121, 2001.
5. Deans DA, Wigmore SJ, Gilmour H, Paterson-Brown S, Ross JA and Fearon KC: Elevated tumour interleukin-1beta is associated with systemic inflammation: A marker of reduced survival in gastro-oesophageal cancer. Br J Cancer 95: 1568-1575, 2006.
6. Chen MF, Lu MS, Chen PT, Chen WC, Lin PY and Lee KD: Role of interleukin 1 beta in esophageal squamous cell carcinoma. J Mol Med 90: 89-100, 2012.
7. Tateno T, Ueno S, Hiwatashi K, Matsumoto M, Okumura H, Setoyama T, Uchikado Y, Sakoda M, Kubo F, Ishigami S, Shinchi H and Natsugoe S: Expression of receptor for advanced glycation end products (RAGE) is related to prognosis in patients with esophageal squamous cell carcinoma. Ann Surg Oncol 16: 440-446. 2009.
8. Deans DA, Wigmore SJ, Gilmour H, Paterson-Brown S, Ross JA and Fearon KC: Elevated tumour interleukin-1beta is associated with systemic inflammation: A marker of reduced survival in gastro-oesophageal cancer. Br J Cancer 95: 1568-1575, 2006.
9. Motoyama S, Miura M, Hinai Y, Maruyama K, Usami S, Saito H, Minamiya Y, Satoh S, Murata K, Suzuki T and Ogawa J: CRP genetic polymorphism is associated with lymph node metastasis in thoracic esophageal squamous cell cancer. Ann Surg Oncol 16: 2479-2485, 2009.
10. Heinhuis B, Netea MG, van den Berg WB, Dinarello CA and Joosten LA: Interleukin-32: a predominantly intracellular proinflammatory mediator that controls cell activation and cell death. Cytokine 60: 321-327, 2012.
11. Shioya M, Nishida A, Yagi Y, Ogawa A, Tsujikawa T, Kim-Mitsuyama S, Takayanagi A, Shimizu N, Fujiyama Y and Andoh A: Epithelial overexpression of interleukin-32alpha in inflammatory bowel disease. Clin Exp Immunol 149: 480-486, 2007.
12. Hata K, Andoh A, Shimada M, Fujino S, Bamba S, Araki Y, Okuno T, Fujiyama Y and Bamba T: IL17 stimulates inflammatory response via NF-kappa B and MAP kinase pathways in human colonic myofibroblasts. Am J Physiol Gastrointest Liver Physiol 282: G1035-1044, 2002.
13. Kobori A, Bamba S, Imaeda H, Ban H, Tsujikawa T, Saito Y, Fujiyama Y and Andoh A: Butyrate stimulates IL32α expression in human intestinal epithelial cell lines. World Gastroenterol 16: 2355-2361, 2010.
14. Felaco P, Castellani ML, De Lutiis MA, Felaco M, Pandolfi F, Salini V, De Amicis D, Vecchiet J, Tete S, Ciampoli C, Conti F, Cerulli G, Caraffa A, Antinolfi P, Cuccurullo C, Perrella A, Theoharides TC, Conti P, Toniato E, Kempuraj D and Shaik YB: IL32: a newly-discovered proinflammatory cytokine. J Biol Regul Homeost Agents 23: 141-147, 2009.
15. Sorrentino C and Di Carlo E: Expression of IL32 in human lung cancer is related to the histotype and metastatic phenotype. Am J Respir Crit Care Med 180: 769-779, 2009.
16. Nishida A, Andoh A, Inatomi O and Fujiyama Y: Interleukin-32 expression in the pancreas. J Biol Chem 284: 17868-17876, 2009.
17. Smith AJ, Toledo CM, Wietgrefe SW, Duan L, Schacker TW, Reilly CS and Haase AT: The immunosuppressive role of IL32 in lymphatic tissue during HIV-1 infection. J Immunol 186: 6576-6584, 2011.
18. Kang YH, Park MY, Yoon DY, Han SR, Lee CI, Ji NY, Myung PK, Lee HG, Kim JW, Yeom YI, Jang YJ, Ahn DK, Kim JW and Song EY: Dysregulation of overexpressed IL32α in hepatocellular carcinoma suppresses cell growth and induces apoptosis through inactivation of NF-eκB and Bcl-2. Cancer Lett 318: 226-233, 2012.
19. Yamaguchi T, Wing JB and Sakaguchi S: Two modes of immune suppression by FOXP3(+) regulatory T-cells under inflammatory or non-inflammatory conditions. Semin Immunol 23: 424-430, 2011.
20. Miyara M and Sakaguchi S: Natural regulatory T cells: mechanisms of suppression. Trends Mol Med 13: 108-116, 2007.
21. Tanchot C, Terme M, Pere H, Tran T, Benhamouda N, Strioga M, Banissi C, Galluzzi L, Kroemer G and Tartour E: Tumor-infiltrating regulatory T cells: phenotype, role, mechanism of expansion in situ and clinical significance. Cancer Microenviron 6: 147-57, 2013.
22. Watanabe MA, Oda JM, Amarante MK and Cesar Voltarelli J: Regulatory T cells and breast cancer: implications for immunopathogenesis. Cancer Metastasis Rev 29: 569-579, 2010.
23. Raghavan S and Quiding-Järbrink M: Regulatory T cells in gastrointestinal tumors. Expert Rev Gastroenterol Hepatol 5: 489-501, 2011.
24. Aoki M, Ishigami S, Uenosono Y, Arigami T, Uchikado Y, Kita Y, Kurahara H, Matsumoto M, Ueno S and Natsugoe S: Expression of BMP-7 in human gastric cancer and its clinical significance. Br J Cancer 104: 714-718, 2011.
25. Sobin LH, Gospodarowicz MK and Wittekind C: TNM classification of malignant tumors. 7th ed. Oxford: Wiley-Blackwell; 2010.
26. Ishigami S, Arigami T, Uchikado Y, Setoyama T, Kita Y, Sasaki K, Okumura H, Kurahara H, Kijima Y, Harada A, Ueno S and Natsugoe S: IL32 expression is an independent prognostic marker for gastric cancer. Med Oncol 30: 472, 2013.
27. Sorrentino C and Di Carlo E: Expression of IL32 in human lung cancer is related to the histotype and metastatic phenotype. Am J Respir Crit Care Med 180: 769-779, 2009.
28. Seo EH, Kang J, Kim KH, Cho MC, Lee S, Kim HJ, Kim JH, Kim EJ, Park DK, Kim SH, Choi YK, Kim JM, Hong JT and Yoon DY: Detection of expressed IL32 in human stomach cancer using ELISA and immunostaining. J Microbiol Biotechnol 18: 1606-1612, 2008.
29. Yousif NG, Al-Amran FG, Hadi N, Lee J and Adrienne J: Expression of IL32 modulates NF-κB and p38 MAP kinase pathways in human esophageal cancer. Cytokine 61: 223-227, 2013.
30. Lee HJ, Liang ZL, Huang SM, Lim JS, Yoon DY, Lee HJ and Kim JM: Overexpression of IL32 is a novel prognostic factor in patients with localized clear cell renal cell carcinoma. Oncol Lett 3: 490-496, 2012.
31. Deng X, Zhang Z, Gu W, Li Y and Liu M: Budesonide inhibits interleukin-32 expression in a rat model of chronic obstructive pulmonary disease. Exp Lung Res 38: 295-301, 2012.